Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.49 |
| ▸ | GSK3A | P49840 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909855 | 0.80 | GSK3B (0.47) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL6069123 | 0.79 | GSK3B (0.57) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL6069007 | 0.79 | GSK3B (0.53) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL6069591 | 0.75 | GSK3B (0.53) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL6068977 | 0.75 | GSK3B (0.50) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL6069014 | 0.74 | GSK3B (0.81) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4399102 | 0.72 | GSK3B (0.67) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5099975 | 0.71 | GSK3B (0.63) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL6069430 | 0.71 | GSK3B (0.47) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5100493 | 0.70 | GSK3B (0.58) | GSK3BGSK3ACDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989382-B2 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040138273-A1 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138273-A1 | Carbocycle based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885CDK1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.